Category
Compounded prescription offering; not a retail capsule comparison
Quantity
Confirm tablet count and strength
Other routes
Injection and nasal products reviewed separately

An oral product within a prescribing service

Shed lists Oral NAD+ Tablets at a starting price of $169 per month, with one month of supply described on the product card. The page presents the tablets alongside compounded injection and nasal options. This review therefore treats them as a distinct prescribed offering, rather than as an interchangeable retail capsule or a product containing an NAD precursor.

That distinction matters because similar wellness terminology can describe different ingredients and regulatory categories. Ask for the actual formulation, tablet quantity, strength and dispensing pharmacy. The public card does not establish all of those details, and the phrase oral NAD+ should not be used to fill them in from a supplement sold by another company.

What the price does and does not cover

The $169 figure is a monthly starting offer. It matches the injection card's starting amount but exceeds the nasal card's $144 figure. Matching prices do not establish matching ingredient quantities, bioavailability or outcomes. They identify commercial options whose clinical and dispensing details still need their own review.

Confirm whether the final quote includes consultation, fulfillment, shipping and follow-up, and whether any additional assessment is needed. Ask about automatic renewal, changes in price and the next billing date. This publication has not purchased the tablet plan or verified a patient-specific invoice, so unlisted fees and future terms remain questions rather than assumptions.

Oral delivery needs its own evidence

The page explains NAD+ through its role in normal cellular processes. That explanation does not demonstrate the absorption or clinical effect of this particular tablet. Evidence about an injection, an infusion, a liposomal capsule or an oral precursor cannot automatically establish a benefit from the finished compounded preparation being proposed here.

Ask the clinician which human studies support the tablet's formulation and intended use. We did not independently verify that it produces the advertised energy or aging-related effects, or that its outcomes are equivalent to the provider's other routes. A convenient oral format can be a practical preference without resolving those evidence questions.

Confirm handling and follow-up before fulfillment

The dispensing pharmacy should supply the actual label, storage conditions and beyond-use information. Tablets should not inherit the assumptions of another oral product with different ingredients or packaging. Also clarify how product-quality concerns are reported and who can answer clinical questions after delivery through the provider's support pathway.

Shed discloses that compounded medications are not FDA-approved. Keep that status visible alongside the fact that a clinician may prescribe the product. The useful comparison here is a separately identified tablet offer with a documented monthly starting price; the final decision still depends on the full formulation, care agreement and relevant evidence, rather than on the shared NAD+ name or the convenience of avoiding another route.

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. Shed: injection, nasal and oral NAD+ offers Provider
  2. FDA: Compounding questions and answers Regulator
  3. PubChem: Nicotinamide adenine dinucleotide Chemical reference